CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity
CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
